Summary A longitudinal study of iron status markers (haemoglobin (Hb), serum (S-) iron, S-transferrin, transferrin saturation, S-ferritin) was performed in 31 chemotherapy treated patients with small cell lung cancer. At discovery, eight patients were anaemic (Hb < 121 g 1-). Hb, S-iron and transferrin saturation were lower (P<0.01), and S-ferritin higher (P<0.01) than in healthy subjects. Chemotherapy induced an immediate fall in Hb (P<0.003), increase in S-iron (P<0.003) and transferrin saturation (P<0.001). Later in the disease a fall in S-transferrin (P<0.006) and an increase in S-ferritin (P<0.02) occurred. Thirty patients died during the 2 years observation. S-ferritin at discovery was correlated to performance status score (r = 0.57, P = 0.01) and to survival (r = -0.63, P<0.0002). Patients with S-ferritin <4001g 1i (n = 13) had longer survival than those with S-ferritin > 400 fig 1-(n = 18) (P = 0.004).
Patients with untreated malignant disease demonstrate characteristic changes in iron metabolism with anaemia, low serum (S-) iron and S-transferrin together with inappropriately elevated S-ferritin (Groop et al., 1978; Lee, 1983) . In general, the administration of cytotoxic agents induces a further fall in haemoglobin (Hb), and an increase in S-iron levels (Alfrey et al., 1966; Doll et al., 1983; Grau et al., 1985; Pollera et al., 1987) . The pathophysiological mechanisms of these changes in iron kinetics are unclarified.
The aim of the present investigation was to study changes in iron status markers in patients with small cell carcinoma of the lung (SCCL), and to evaluate their relation to survival.
Material and methods
The material comprised 34 consecutive patients with SCCL; two were excluded due to short survival <1 month, and one due to porphyria cutanea tarda with iron overload. Median age in the included 31 patients (24 males, seven females) was 64 years (range 39-76 Haemoglobin Eight patients (26%) had Hb values< 121 g 1-(7.5 mmol l-) at discovery, vs 12 (40%) at the last measurement before death. There was a marked decline in Hb levels during the disease, the major fall occurring 1 month after initiation of chemotherapy (Table I, Figure 1 ).
Iron status markers S-iron showed a significant increase from discovery to death. The major increase was observed within 1 month after initiation of chemotherapy. S-transferrin demonstrated a decline occurring gradually and being significant from the third month of survival. Transferrin saturation showed a significant increase, being most pronounced in the first 3-4 months after initiation of chemotherapy. None of the patients displayed values < 15%. High values> 60% were observed in 5 (17%) patients shortly before death. S-ferritin demonstrated a significant rise, which occurred late in the disease, after 10-11 months of survival (Figure 2 ). The distributions of S-ferritin values are shown in Table II Survival PS was correlated to survival (r =-0.37, P = 0.05). S-transferrin at discovery was correlated to survival (r = 0.44, P < 0.02), but closer analysis showed that this relation was of no clinical relevance. S-ferritin at discovery showed a negative correlation to survival (log vs log values, r = -0.63, P< 0.0002, Figure 3) . Analysis of survival rates revealed that a threshold ferritin value of 400 ytg 1' yielded the best discrimination between the two survival groups (Figure 4 ). Furthermore S-ferritin at discovery was correlated to PS (r = 0.57, P = 0.01). Iron status markers at death showed no correlation to survival.
Discussion
Iron status in patients with SCCL was profoundly influenced by disease and chemotherapy. Prior to treatment, Hb values were low and many patients were anaemic. Chemotherapy was immediately followed by a decrease in Hb levels due to inhibition of erythropoiesis (Alfrey et al., 1966 ); the addi- tional fall prior to death was probably caused by metastatic marrow invasion.
Before chemotherapy, the patients were hyposideraemic, consistent with the fact that malignant disease produce an impaired release of iron from the storage compartments and a fall in S-iron (Lee, 1983; Lipschitz et al., 1971) . Chemotherapy induced a rise in S-iron levels, as described in other investigations (Grau et al., 1985; Pollera et al., 1987) . The rise begins already 24-48 h after initiation of therapy (Pollera et al., 1987) . Throughout the remaining period of disease, S-iron remained elevated. The reasons for these changes in S-iron are unknown. Haemolysis can be excluded according to previous studies (Doll et al., 1983; Pollera et al., 1987) , and increased iron absorption or decreased excretion are unlikely to give these rapid fluctuations. A decreased Hb synthesis per se induces a moderate rise in S-iron, as erythropoiesis modulates the release of iron from storage compartments (Alfrey et al., 1966) .
S-transferrin values at discovery were of the same order as in healthy subjects, but declined after 3-4 months of disease. Malignancies are known to reduce S-transferrin levels, probably due to decreased synthesis combined with increased catabolism (Hughes et al., 1972; Lee, 1983) .
The increase in transferrin saturation was a consequence of the rise in S-iron, combined with an almost constant Stransferrin level. None of the patients had values <15%, indicating insufficient iron delivery to the erythron. Later in the disease, there was a rise in saturation due to declining S-transferrin and a further increase in S-iron.
In healthy subjects, the S-ferritin concentration reflects mobilisable iron stores, mainly located in the liver, spleen and bone marrow (Walters et al., 1973) lg 1-1 of 'normal' and > 300 jig 1' of 'increased' iron stores (Milman et al., 1983) .
To some extent S-ferritin behaves as an acute phase reactant, being inappropriately elevated in infectious, inflammatory and malignant diseases (Gropp et al., 1978; Lee, 1983) . S-ferritin was elevated at discovery and remained relatively constant until late in the disease, where a marked rise was observed at 10-11 months, probably reflecting an increased tumour mass. The present ferritin assay uses antibodies against basic spleen ferritin, and thus underestimates the presence of acidic ferritin often produced in malignant tumours (Hazard et al., 1977) .
Prognostic indicators of survival are of importance to the clinician in the decision for treatment. In a study comprising 778 patients with SCCL (0sterlind et al., 1986) , a number of clinical and biochemical variables (not including iron status markers) were tested against survival. PS at the time of diagnosis appeared to be the most weighty single factor. In the present study, PS also correlated to survival. Furthermore, there was a pronounced correlation between S-ferritin at discovery and survival, which was higher than the correlation between PS and survival. A threshold S-ferritin value of 400 tLg 1`divided the patients in groups with highly significant differences in survival, i.e. high ferritin levels were related to a short survival. Cox et al. (1986) also found a relation between S-ferritin and survival in SCCL, using a discriminative value of 600 tig 1'. Whether S-ferritin may be of clinical significance in the future evaluation of the prognosis in patients with SCCL should be investigated in more comprehensive studies.
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